ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rF1V-1018

Its studies are mostly in Vaccine-Preventable Diseases, led by Sanofi.

Furthest: phase 2, since Aug 10, 20222 company-led studies, 1 open or runningNext primary completion: Jan 29, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi21 open or runningphase 2since Aug 10, 2022Aug 10, 2022Jan 29, 2027phase 2 · NCT07207408

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 10, 2022First study: phase 2 study in PlagueFirst studyNCT05506969 · 200 enrolled · United States
  2. Oct 2, 2025Phase 2 study in Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia PestisNCT07207408 · 148 enrolled · United States

Ahead

  1. Jan 29, 2027Primary completion: phase 2 study in Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia PestisNCT07207408

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07207408Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis · United States2Active, not recruitingJan 29, 2027148
NCT05506969Plague · United States2CompletedOct 3, 2023200

How it is read

Names in the registry

  • “rF1V-1018”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.